REVIEW

Metabolic regulation of immune responses to cancer

Jannis Wißfeld1,2*, Anke Werner1,2*, Xin Yan1,2,3*, Nora ten Bosch1,2*, Guoliang Cui1,2,3
1Helmholtz Institute for Translational Oncology (HI-TRON), Mainz 55131, Germany; 2T Cell Metabolism Group (D192), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany; 3Faculty of Biosciences, Heidelberg University, Heidelberg 69120, Germany

ABSTRACT

The tumor microenvironment is an ecosystem composed of multiple types of cells, such as tumor cells, immune cells, and cancer-associated fibroblasts. Cancer cells grow faster than non-cancerous cells and consume larger amounts of nutrients. The rapid growth characteristic of cancer cells fundamentally alters nutrient availability in the tumor microenvironment and results in reprogramming of immune cell metabolic pathways. Accumulating evidence suggests that cellular metabolism of nutrients, such as lipids and amino acids, beyond being essential to meet the bioenergetic and biosynthetic demands of immune cells, also regulates a broad spectrum of cellular signal transduction, and influences immune cell survival, differentiation, and anti-tumor effector function. The cancer immunometabolism research field is rapidly evolving, and exciting new discoveries are reported in high-profile journals nearly weekly. Therefore, all new findings in this field cannot be summarized within this short review. Instead, this review is intended to provide a brief introduction to this rapidly developing research field, with a focus on the metabolism of two classes of important nutrients—lipids and amino acids—in immune cells. We highlight recent research on the roles of lipids and amino acids in regulating the metabolic fitness and immunological functions of T cells, macrophages, and natural killer cells in the tumor microenvironment. Furthermore, we discuss the possibility of “editing” metabolic pathways in immune cells to act synergistically with currently available immunotherapies in enhancing anti-tumor immune responses.

KEYWORDS

Lipids; amino acids; cancer; anti-tumor immunity; T cells; NK cells; metabolism; immunometabolism

Introduction

In recent decades, cancer research has made substantial progress in the understanding of cancer biology and the development of therapy approaches against specific cancers. Scientists from the German Cancer Research Center (DKFZ) have been major drivers in this process. In 1989, a research group from DKFZ found that monoclonal antibodies targeting APO-1 (also known as CD95 or FasR) on human lymphoma cells trigger apoptosis of lymphoma cells in vivo and induce regression of lymphoma in a mouse model. A broad spectrum of tumor cells express the ligand of APO-1, APO-1L (also known as CD95L, CD178, and FasL), which induces apoptosis of APO-1-expressing lymphocytes in vitro, in a process called tumor counterattack. In vivo, the interaction between APO-1 and APO-1L delays tumor growth in a neutrophil-independent manner. More recent approaches target mechanisms of T cell exhaustion, a term used interchangeably with T cell dysfunction herein, and enhance anti-tumor immunity by using immune checkpoint blockade-based treatments. The most frequent targets are CTLA-4, PD-1, and its ligand PD-L1. In addition, combinatory treatments such as anti-CD40 and an inhibitor of MAPK and ERK have been found to be promising candidates. This polytherapy synergistically suppresses Kras mutation-driven pancreatic ductal adenocarcinoma. Moreover, inhibition of C-X-C motif chemokine 12 (CXCL12) has been found to promote T cell accumulation and to act synergistically with checkpoint inhibitors, thus providing clinical benefits to patients with advanced stage pretreated metastatic colorectal and pancreatic cancer in a phase I/II trial. Furthermore, IL-10 prevents excessive activation-induced exhaustion of CD8+ T cells in a model of chronic lymphocytic leukemia and delays the development of leukemia. Finally, our group has found that T cells express regulator of G-protein signaling (Rgs)-16 at high levels. Rgs16...
deficiency inhibits CD8\(^+\) T cell apoptosis and acts synergistically with PD-1 blockade in enhancing anti-tumor CD8\(^+\) T cell responses. Human RGS16 mRNA expression levels in the CD8\(^+\) tumor-infiltrating T cells of patients with melanoma negatively correlate with the expression of genes associated with T cell stemness and are predictive of low responses to PD-1 blockade\(^8\).

However, checkpoint blockade therapy approaches have been only partially successful. Consequently, the influence of the tumor microenvironment (TME) on anti-tumor immunity and the field of immunometabolism have become a focus. Tumor-derived metabolic stimuli shape the TME into an immunosuppressive region, thereby hampering therapeutic approaches. In a mouse model of non-viral hepatocellular carcinoma (HCC), nonalcoholic steatohepatitis has been found to induce HCC. Liver-resident CD8\(^+\) T cells are sensitive to metabolic stimuli and are aberrantly activated by anti-PD-1 treatment. These auto-reactive CD8\(^+\)PD-1\(^+\) T cells cause tissue damage instead of leading to HCC regression. Depleting CD8\(^+\) T cells or neutralizing TNF\(\alpha\) has been found to ameliorate HCC progression in mice receiving anti-PD1, thus suggesting a rationale for stratifying patients with HCC according to etiology before immune checkpoint-based immunotherapy\(^9,10\). Kupffer cell-derived reactive oxygen species and TNF\(\alpha\) promote cholangiocellular proliferation and oncogenic transformation. Depletion of Kupffer cells or blocking the TNF\(\alpha\) signaling pathway decreases cholangiocellular oncogenic transformation\(^11\). Furthermore, macrophage-derived NO is required for the expression of vessel adhesion molecules, which are required for T cell extravasation and infiltration into tumors\(^12\). Interestingly, alterations of nutrient availability in the TME have also been shown to affect anti-tumor immunity. These alterations can be triggered by genetic mutations, which reprogram tumor cell metabolic pathways\(^13\). Our laboratory has found that CD8\(^+\) T cells in tumors increase the uptake of oxidized low-density lipoprotein (oxLDL) in a CD36-dependent manner. OxLDL promotes CD8\(^+\) T cell exhaustion through lipid peroxidation\(^14\). Moreover, the amino acid tryptophan is catabolized by tryptophan-2,3-dioxygenase and indoleamine 2,3 dioxygenase (IDO) in human tumor cells into kynurenine, an endogenous ligand of the transcription factor aryl hydrocarbon receptor (AHR). Kynurenine potently suppresses antitumor immune responses\(^15\), as extensively discussed in a later section herein. A recent study has revealed that the L-amino acid oxidase interleukin-4-induced-1 (IL4I1) generates indole metabolites and kynurenic acid, which are agonists of AHR, thereby promoting cancer cell motility and suppressing adaptive immunity. Because IDO inhibitors do not block IL4I1, these findings may explain the failure of a phase III clinical trial combining immune checkpoint blockade with IDO1 inhibition for cancer treatment\(^16\). An additional important finding of DKFZ scientists was that tumor cells with mutations in the isocitrate dehydrogenase gene produce the oncometabolite (R)-2-hydroxyglutarate, which inhibits immune responses and promotes tumor immunosuppression in the TME\(^17\).

These recent advances in immunometabolism research underscore the importance of understanding how the altered availability of nutrients, including glucose, lipids, and amino acids, in the TME changes anti-tumor immunity. In this review, we discuss the influence of changes in lipid and amino acid content within the TME on anti-tumor immunity. The role of glucose metabolism on immune responses to cancer has been extensively reviewed elsewhere and thus will not be discussed here\(^18-22\).

**Lipid metabolism regulates immune responses to tumors**

Lipids are a diverse class of biomolecules with multiple important functions, such as serving as structural components of cell membranes, producing energy, and transducing intracellular and intercellular signals. Structural lipids, including phospholipids, sphingolipids, and cholesterol, are the major components of the plasma membrane, whereas fatty acids provide a basis for cellular bioenergetics through the \(\beta\)-oxidation pathway. Furthermore, several lipid molecules bind intracellular receptors, including peroxisome proliferator-activated receptors (PPARs) and sterol regulatory element-binding protein (SREBP), and subsequently regulate the transcription of genes involved in energy homeostasis and inflammation\(^23\). Several lines of evidence suggest that lipids are enriched in the TME and are required for immune cells to meet energy demands. However, certain lipid species in the TME cause immunosuppression, and promote cancer survival and metastasis\(^14,23,24\). In this section, we discuss the complicated immunosupportive or immunosuppressive roles of lipid species, such as fatty acids, cholesterol, and oxLDL (Figure 1).

**T cells**

T cells are important mediators of anti-tumor immunity. CD8\(^+\) cytotoxic T lymphocytes directly or indirectly kill cancer
Figure 1  Lipid metabolism impairs anti-tumor immunity. In the lipid-rich TME, infiltrating CD8\(^+\) T cells upregulate CD36 or FATPs, thereby increasing lipid uptake. Lipid accumulation and subsequent storage in lipid droplets results in a metabolic switch toward fatty acid oxidation (FAO) via STAT3 and CPT1, thus decreasing CD8\(^+\) T cell proliferation, survival, and overall effector function, but increasing susceptibility to ferroptosis and lipotoxicity. In contrast, T\(_{reg}\) cells use FAO and oxidative phosphorylation to sustain their immunosuppressive phenotype in a FoxP3-dependent manner through downregulation of GLUT1 and the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin complex 1 (mTORC1) pathway. Lipid accumulation in DCS is mediated by MSR1/CD204 as well as in an XBP1-dependent manner, and it interferes with TLR stimulation and proliferation of DCS. Furthermore, accumulated lipids impair antigen processing and cross-presentation by HSP70 resorption. Neutrophils accumulate lipids via CD36/FATPs and produce leukotrienes via ALOX5. Lipid droplets are then transferred to metastasis-initiating tumor cells, where they facilitate survival. Natural killer (NK) cells show an impaired metabolic profile characterized by PPAR-\(\alpha/\delta\)-driven lipid accumulation and a decrease in phosphoinositide 3-kinase-Akt-mTORC1 signaling. This metabolic shift results in decreased secretion of effector cytokines, granzymes, and perforin, as well as decreased tumor cell lysis. Tumor-associated macrophages (TAMs) increase lipid uptake and storage, as well as PPAR-\(\gamma\) signaling via FAO and STAT6, thus increasing the secretion of tumor promoting and anti-inflammatory factors, and supporting angiogenesis and metastasis. Abbreviations: Akt, Akt serine/threonine kinase 1; ALOX5, arachidonate 5-lipoxygenase; ARG1, arginase 1; CCL22, chemokine (C-C motif) ligand 22; CD, cluster of differentiation; CPT1, carnitine palmitoyltransferase 1; DC, dendritic cell; FAO, fatty acid oxidation; FATP, fatty acid transport protein; FoxP3, forkhead box P3; GLUT1, glucose transporter 1; HSP70, heat shock protein 70 kDa; IFN-\(\gamma\), interferon \(\gamma\); IL, interleukin; MHC, major histocompatibility complex; MMP9, matrix metalloproteinase 9; MSR1, macrophage scavenger receptor 1; mTORC1, mechanistic target of rapamycin kinase complex 1; NO, nitric oxide; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; PPAR, peroxisome proliferator activated receptor; STAT, signal transducer and activator of transcription; TAM, tumor-associated macrophage; TME, tumor microenvironment; T\(_{reg}\), regulatory T cells; XBP1, X-box binding protein 1.

Parts of the figure were drawn by using original or modified pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/).
and T cells must compete with cancer cells for this scarce nutrient\textsuperscript{26,27}. To that end, T cells increase their reliance on lipids for energy production\textsuperscript{24}. Promotion of fatty acid β-oxidation through treatment with the PPAR\textsubscript{α} agonist fenofibrate improves CD8\textsuperscript{+} T cell multifunctionality in a mouse melanoma model and delays tumor progression\textsuperscript{24}. Furthermore, bezafibrate, a pan-agonist for all PPAR isoforms, increases fatty acid β-oxidation, oxidative phosphorylation, glycolysis, and CD8\textsuperscript{+} T cell survival, and restores CD8\textsuperscript{+} T cell effector function in combination with anti-PD-L1 therapy in a sarcoma mouse model, via upregulation of carnitine palmitoyltransferase I (CPT1) α and B cell lymphoma 2 (BCL2)\textsuperscript{28}. Moreover, activation of PPAR\textsubscript{α} and PPAR\textsubscript{β/δ} via the tool compound GW501516 increases CPT1α expression and fatty acid β-oxidation, which are accompanied by enhanced production of IFNγ and prolonged survival of mice in an adoptive cell therapy model\textsuperscript{29}.

However, excessive lipid enrichment in the TME causes CD8\textsuperscript{+} T cell exhaustion. Tumor-infiltrating CD8\textsuperscript{+} T cells adapt to the lipid-rich TME by upregulating the expression of lipid transport proteins, such as CD36, which imports fatty acids including long-chain fatty acids (LCFA)\textsuperscript{14,30}. The intracellular accumulation of LCFA drives CD8\textsuperscript{+} T cell dysfunction by inducing lipotoxicity. This LCFA-induced immunosuppression is further enhanced by the downregulation of very long-chain acyl-CoA dehydrogenase, an enzyme required to metabolize fatty acids, thus further increasing LCFA accumulation and exacerbating lipotoxicity\textsuperscript{30}. Beyond fatty acids, CD36 is required to import oxLDL, a lipid species abundant in the TME\textsuperscript{14}. OxLDL uptake into tumor-infiltrating CD8\textsuperscript{+} T cells promotes lipid peroxidation and ferroptosis of exhausted CD8\textsuperscript{+} T cells. Overexpression of the glutathione peroxidase GPX4, an antioxidant defense enzyme, enhances anti-tumor CD8\textsuperscript{+} T cell function\textsuperscript{14}. One intriguing question is which molecular pathways drive tumor-infiltrating CD8\textsuperscript{+} T cells to adapt to the glucose-poor and lipid-rich TME. The interaction between PD-1 and its ligand PD-L1 inhibits glycolysis and promotes fatty acid β-oxidation in CD8\textsuperscript{+} T cells\textsuperscript{26,31,32}, and glycolysis inhibition suppresses CD8\textsuperscript{+} T cell effector function\textsuperscript{33-35}. PD-1 ligation activates signal transducer and activator of transcription 3 (STAT3), which in turn mediates the metabolic switch from glycolysis to fatty acid β-oxidation in CD8\textsuperscript{+} T cells in a mouse model of spontaneously developed mammary tumors\textsuperscript{32}.

Another subset of immune cells, CD4\textsuperscript{+} FoxP3\textsuperscript{+} regulatory T (T\textsubscript{reg}) cells, despite being functionally distinct from CD8\textsuperscript{+} T cells, require fatty acid β-oxidation to exert their immunoregulatory function\textsuperscript{36,37}. FoxP3, the key transcription factor of T\textsubscript{reg} cells, promotes the expression of genes involved in oxidative metabolism at the expense of genes associated with glycolysis\textsuperscript{38,39}. FoxP3 protects T\textsubscript{reg} cells against lipid enrichment-mediated lipotoxicity by enhancing fatty acid β-oxidation and thereby decreasing fatty acid accumulation\textsuperscript{40}.

Beyond fatty acids, cholesterol is also enriched in the TME, and tumor-infiltrating CD8\textsuperscript{+} T cells adapt to the cholesterol enrichment by increasing their uptake of cholesterol beyond that in splenic CD8\textsuperscript{+} T cells\textsuperscript{14}. An increase in cholesterol in CD8\textsuperscript{+} T cells results in endoplasmic reticulum stress and T cell dysfunction\textsuperscript{41}, a phenotype similar to that of CD8\textsuperscript{+} T cells deficient in synthesizing sphingolipids\textsuperscript{42}. Plasma membrane cholesterol promotes T cell receptor clustering and enhances immunological synapse formation\textsuperscript{43}. Genetic deficiency or pharmacological inhibition of acyl-CoA:cholesterol acyltransferase 1 (ACAT1), a key enzyme catalyzing cholesterol esterification, enhances the effector function and proliferation of CD8\textsuperscript{+} T cells and limits melanoma growth as well as metastasis in mice, owing to an increase in plasma membrane cholesterol.

**Natural killer (NK) cells**

NK cells are part of the innate immune system and are potent producers of cytokines, including IFNγ and TNFα. Similarly to CD8\textsuperscript{+} cytotoxic T lymphocytes, NK cells kill malignant cells through the release of cytotoxic agents, such as perforins and granzymes, or through death receptor-ligand engagement\textsuperscript{44,45}. The influence of dietary lipids on NK cell effector function has been studied intensively. Obesity is inversely correlated with NK cell proliferation and cancer cell cytolytic activity in both humans and mouse models\textsuperscript{46-48}, thus implying that NK cell effector function is inhibited by lipids. Prostaglandin E is a physiologically active lipid produced by thyroid cancer cells\textsuperscript{49}. Cancer cell-derived prostaglandin E inhibits NK cell effector cytokine production and suppresses the cytolytic activity of NK cells. Inhibition of the prostaglandin E\textsubscript{2} receptor EP4 by RQ-15986 has been found to rescue the effector function of NK cells and to inhibit metastasis in a mouse model of metastatic breast cancer\textsuperscript{50}. Furthermore, NK cells in diffuse large B cell lymphoma undergo metabolic and transcriptional reprogramming characteristic of an increase in lipid metabolism. Exposure of NK cells to a cocktail of lipids impairs NK cell function, similarly to the NK cell dysfunction observed in the lymphoma environment\textsuperscript{51}. PPAR\textsubscript{α} and PPAR\textsubscript{β/δ} increase the
expression of the lipid transport protein CD36 and low-density lipoprotein receptor, thus increasing lipid uptake and accumulation in NK cells. Lipid accumulation causes a dysfunctional NK cell phenotype characterized by decreased production of effector cytokines and tumor cell lysis. The CPT1 inhibitor etomoxir restores the cytotoxicity of NK cells52. Similarly to PPAR, SREBP family transcription factors are conventionally known as master regulators of lipid homeostasis. SREBPs play essential roles in interleukin-2 (IL-2) and IL-12-induced metabolic reprogramming of NK cells, independently of their role in regulating lipid biosynthesis. NK cells require SREBP to elevate glycolysis and engage the citrate-malate shuttle, thereby producing IFNγ and exerting cytotoxicity53. These results shed light on the multifunctional properties of key transcription factors regulating cellular metabolism.

**Tumor-associated macrophages (TAMs)**

TAMs are present in many types of tumors, and their abundance is positively correlated with cancer progression and poor clinical outcomes54-58. Macrophages are broadly classified into pro-inflammatory (M1) and anti-inflammatory (M2) macrophages, although they display a broad spectrum of intermediate phenotypes between M1 and M2 macrophages59,60. This classification echoes the early definition of “classically activated macrophages” and “alternatively activated macrophages”61-63. Metabolites in the TME, such as lactate and fatty acids, promote the differentiation of TAMs into an M2-like phenotype64,65. TAMs inhibit anti-tumor immune responses through the secretion of IL-1066,67 and TGFB68,69, and the recruitment of Treg cells via the chemokine CCL270. They also promote angiogenesis by secreting vascular endothelial growth factor71-73 and promote metastasis by digesting extracellular matrix proteins74-77. The role of fatty acid β-oxidation in IL-4-driven M2 macrophage differentiation remains debated. Some studies have suggested that TAMs increase CD36 expression to import lipids for energy production. Fatty acid β-oxidation promotes reactive oxygen species production and IL-4-STAT6 activation, and is critical for TAM polarization. In addition, CD36-dependent uptake of triacylglycerol, and subsequent lipolysis and oxidation, are required for M2 macrophage activation65. Uptake of oxLDL by CD36 results in increased PPAR-γ signaling, which in turn promotes CD36 expression and fatty acid β-oxidation78-80. Moreover, uptake of LDL and oxLDL by the scavenger receptor MARCO fosters formation of lipid-loaded TAMs, which release CCL6 and thereby promote cancer cell migration81.

In contrast, deficiency in CPT1a and CPT2 proteins, which are required for transporting long-chain fatty acids into the mitochondria for β-oxidation, do not affect IL-4-driven M2 macrophage differentiation82. Regardless of the complicated roles of fatty acid β-oxidation in IL-4-driven M2 macrophage differentiation, unsaturated fatty acids such as olate promote the immunosuppressive and pro-tumor phenotype of TAMs through lipid droplet-dependent mechanisms83. In addition, SREBP1-dependent production of anti-inflammatory fatty acids contributes to the resolution of TLR4-mediated inflammation84, and Caveolin-1 participates in LXR-dependent cholesterol efflux and mediates anti-inflammatory properties85. Similarly, ovarian cancer cells facilitate membrane cholesterol efflux in TAMs, thus resulting in lipid raft breakdown and a subsequent increase in IL-4 signaling, which fosters the immunosuppressive TAM phenotype86.

**Dendritic cells (DCs)**

DCs are professional antigen-presenting cells with essential roles in activating antigen-specific T cells. The immunostimulatory function of DCs has been shown to be inhibited by a high-fat diet87. Administration of polyunsaturated fatty acids attenuates DC activation and maturation88,89. Intracellular lipid accumulation affects antigen presentation and subsequent activation of tumor antigen-specific T cells by DCs. Briefly, the macrophage scavenger receptor (MSR1) increases lipid uptake by DCs. Lipid-laden DCs have a diminished ability to stimulate the proliferation of antigen-specific T cells, owing to defects in antigen processing90. Msr1 deficiency rescues the ability of DCs to activate antigen-specific T cells91. Furthermore, oxidized lipids, but not non-oxidized lipids, impair DC antigen cross-presentation92. Lipid peroxidation byproducts activate endoplasmic reticulum stress response factor X-box binding protein 1 (XBP1), thus resulting in lipid overloading and the inhibition of DC-mediated activation of anti-tumor T cells in metastatic ovarian cancer93. Oxidatively truncated lipid bodies in DCs bind heat shock protein 70 (Hsp70), a protein required for trafficking of peptide-major histocompatibility complex (MHC) class I complexes to the DC cell surface. Thus, the binding of oxidatively truncated lipid bodies to Hsp70 affects peptide-MHC trafficking to the DC cell surface and disrupts DC-mediated antigen cross-presentation in cancer94.

**Neutrophils**

Neutrophils suppress anti-tumor immune responses and support metastasis by producing leukotrienes95,96. Leukotrienes...
are bioactive lipid species that stimulate selective expansion of a subset of cancer cells with high tumorigenic potential, thus promoting tumor cell colonization of distant tissues in a mouse model of breast cancer. The production of leukotrienes is dependent on the enzyme arachidonate 5-lipoxygenase (Alox5). Inhibition of Alox5 reverses neutrophil-dependent tumor cell metastasis. The ability of neutrophils to facilitate the initiation of metastasis is associated with the accumulation of neutral lipids. In pre-metastatic states, neutrophils decrease adipose triglyceride lipase activity, thus leading to lipid accumulation. Neutrophils subsequently transfer lipids to metastatic tumor cells through a macropinocytosis-lysosome pathway, which increases tumor cell survival and proliferative ability. In addition, tumor-derived oxysterols have been reported to recruit pro-tumor neutrophils in a manner dependent on C-X-C motif chemokine receptor 2, which in turn suppresses anti-tumor immune responses and supports tumor growth. Collectively, lipids mediate the bi-directional communication between tumor cells and neutrophils, and cause immunosuppression and metastasis.

**Roles of amino acids in anti-tumor immunity**

Amino acids serve not only as building blocks for protein synthesis but also as precursors for many metabolites and signaling molecules involved in numerous intracellular and intercellular signal transduction pathways. Therefore, amino acid metabolism is essential for cell proliferation, survival, and function. More than 30 years ago, Chuang et al. demonstrated that deficiency in amino acids, including arginine, glutamine, leucine, threonine, and tryptophan, inhibits T cell proliferation. This study was followed by many publications in recent decades highlighting the importance of amino acids in T cell proliferation, effector function, and differentiation. The availability of amino acids in the TME is substantially different from that in non-tumor tissues, thus prompting the question of whether amino acids and their metabolites regulate T cell exhaustion in the TME. Whereas variations in certain amino acids, e.g., glutamine, are probably based on the increased uptake by cancer cells, concentrations of these nutrients fluctuate depending on the tumor type. However, one common feature of several cancer entities is the upregulation of the arginine and tryptophan degrading enzymes arginase and IDO, respectively. Therefore, in this part of the review, we focus on arginine and tryptophan as examples to discuss the roles of amino acids in shaping the immunosuppressive nature of the TME (Figure 2).

**Arginine**

Arginine is a basic proteinogenic amino acid involved in various metabolic pathways, including the synthesis of nitric oxide, polyamines, and collagen. Arginine is also a key activator of mammalian target of rapamycin (mTOR), an important gatekeeper regulating cell growth, proliferation, and survival. Arginine is defined as a semi-essential amino acid; i.e., although cells can synthesize arginine from the neutral amino acid citrulline through a two-step biochemical reaction involving the enzymes argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL), it becomes limiting in certain situations with substantially elevated demand for arginine, such as cancer and chronic inflammation. The concentrations of arginine in the plasma of healthy humans range between 70 and 120 μM, and are higher than those in tumor interstitial fluids or the plasma in humans and mice with hematological malignancies. Furthermore, the concentrations of arginine vary and are significantly lower in the core regions than the peripheral regions of tumors. The mechanisms of arginine depletion in tumor tissues have been intensively investigated. One plausible explanation is that arginine is consumed at high rates by rapidly growing cancer cells. Furthermore, tumor-infiltrating myeloid cells and cancer cells express arginase 1, which hydrolyzes arginine into ornithine and urea. Arginase 1 breaks down arginine through several intracellular and extracellular mechanisms: (i) cells increase uptake of arginine through the cationic amino acid transporter CAT2B, and arginine is then hydrolyzed by intracellular arginase 1, or (ii) cells secrete arginase 1 into the extracellular compartment, where it hydrolyzes free arginine into ornithine and urea. Ornithine is a precursor of polyamines such as putrescine, spermine, and spermidine, which are necessary for cell proliferation.

**T cells**

Arginine plays an essential role in T cell activation and proliferation. The proliferation of both murine and human T cells is
completely inhibited when T cells are cultured in arginine-free medium\textsuperscript{110,122,123}. Comparable results have been obtained when regular cell culture medium is supplemented with arginase, whereas T cell proliferation is restored by the addition of an arginase inhibitor \textsuperscript{110,124,125}. Furthermore, murine T cell proliferation is rescued in arginase-treated medium in the presence of the neutral amino acid citrulline, which is used as a substrate for the enzymes ASS and ASL to synthesize arginine\textsuperscript{125}. In contrast, human T cells are not able to synthesize arginine intracellularly, owing to insufficient ASS expression in the absence of arginine\textsuperscript{122,126}. The gene encoding the ASS protein is argininosuccinate synthetase 1 (ASS1). ASS1 is a direct target of the transcription factors activating transcription factor 4 (ATF4) and CCAAT/enhancer binding protein β (C/EBPβ). Despite the presence of ATF4 and C/EBPβ, ASS1 is not expressed in human T cells stimulated in the absence of arginine. Arginine starvation induces genome-wide chromatin compaction and increases H3 lysine-9/lysine-27 trimethylation, thus decreasing DNA accessibility, and disrupting ATF4 and C/EBPβ binding at target genes\textsuperscript{122}. Because of their
inability to synthesize arginine intracellularly, human T cells depend on the uptake of arginine from the extracellular space, a process mediated by cationic amino acid transporter 1 (CAT-1). Blocking this CAT-mediated arginine transport significantly decreases T cell proliferation and survival.

Arginine deprivation affects T cell proliferation through multiple mechanisms, such as cell cycle arrest, decreased CD3ζ chain expression, insufficient T cell receptor signaling, decreased expression of IL-2 receptor α (CD25) and effector cytokines, and impairment of T cell metabolic fitness. Arginine increases cyclin D3 expression at the transcriptional, posttranscriptional, and translational levels. Arginine starvation decreases the expression of cyclin D3, thus resulting in cell cycle arrest in G0-G1 phase. In addition, arginine availability decreases the expression of cyclin D3, thus resulting in insufficient TCR signaling to activate T cells. T cells with diminished expression of CD3ζ chain have been found in tumors of patients with non-small cell lung carcinoma and a murine Lewis lung carcinoma (3LL) model, and are accompanied by elevated arginase expression in tumor cells and CAT-2B-mediated arginine uptake in arginase-expressing tumor-associated myeloid cells. Interestingly, this arginine deprivation-mediated inhibitory effect on CD3ζ chain expression appears to be specific to arginine, because the depletion of other amino acids, such as glutamine, glycine, leucine, and lysine, does not change the CD3ζ chain expression level. The efficient formation of the immune synapse is a prerequisite for signal transmission between antigen presenting cells and T cells. The dephosphorylation of the actin-binding protein cofilin is required to induce remodeling of the actin cytoskeleton in T cells. Arginine deprivation increases cofilin phosphorylation in T cells, thus impairing formation of the immunological synapse. Furthermore, phorbol 12-myristate 13-acetate (PMA) and ionomycin-induced T cell activation are impaired by arginine deprivation. Because PMA and ionomycin bypass the requirement for CD3ζ chain to activate T cells, arginine depletion appears to impair T cell activation not only by affecting the CD3ζ chain-associated T cell receptor proximal signaling components but also potentially by inhibiting the distal signaling components. Moreover, the expression of IL-2 receptor α chain significantly decreases under arginine deprivation, thereby indicating that arginine is indispensable for IL-2 signaling—a key signaling pathway required for T cell proliferation. Beyond IL-2 receptor α, cytokines including IFNγ, TNFα, IL-5, and IL-10, which play important roles in T cell differentiation and effector function, are produced at low levels by T cells cultured in the absence of arginine. Arginine deprivation impairs glycolysis, the pentose phosphate pathway, the tricarboxylic acid cycle, and mTORC1 activity. In line with these findings, elevated arginine concentrations significantly increase the survival of human and murine CD8+ T cells, and the anti-tumor activity of CD8+ T cells in a B16 melanoma mouse model. This enhanced survival is accompanied by a shift in metabolic status from glycolysis toward mitochondrial respiration in the presence of high concentrations of arginine. Furthermore, high concentrations of arginine promote T cell differentiation into a central memory T cell-like phenotype, thus favoring the long-term persistence of anti-tumor CD8+ T cells.

Because arginine plays essential roles in T cell activation and proliferation, inhibition of arginase has led to enthusiasm for reviving arginase-mediated dysfunctional T cells. For example, inhibition of PMN-derived arginase increases human T cell proliferation and induces higher levels of production of effector cytokines, such as IFNγ, IL-9, and IL-17. Furthermore, inhibition of arginase increases the expression of CD25 and re-expression of CD28 after the initial stimulation-induced downregulation. Of note, the inhibition of arginase activity also reverses the anergic state of T cells in patients with multiple myeloma.

**NK cells**

Similarly to T cells, NK cells require arginine for optimal proliferation. Arginine deprivation impairs the proliferation of murine and human NK cells induced by multiple stimuli, including IL-2 and PMA/ionomycin. Compared with T cells, NK cells are less sensitive to low arginine levels. For example, T cells require arginine at a concentration of 20 μM to achieve half maximal proliferation, whereas 2 μM arginine is sufficient for NK cell half maximal proliferation. Notably, NK cell viability is not affected by arginine starvation. Similarly to that on T cells, ζ chain expression on NK cells is decreased by arginine starvation, thus impairing downstream signal transduction and decreasing NK cell cytotoxicity. One report has shown that NK cell granule exocytosis and cytotoxicity are independent of extracellular arginine. Despite the contradictory description of the influence of arginine deprivation on NK cytotoxicity, one commonality among reports is that arginine deprivation impairs IFNγ expression in NK cells through a post-transcriptional mechanism. Additional evidence supporting the inhibitory role of arginine deprivation on NK cells is that arginase activity has been detected in...
damage-associated molecular patterns derived from mito-
chondrial preparations (MitoDAMPs)\textsuperscript{139}. MitoDAMPs impair IFN\(\gamma\) secretion by NK cells and decrease the expression of the NK cell activating receptor NKG2D. The inhibitory effects of MitoDAMPs are reversed by the addition of extracellular argi-
nine or an arginase inhibitor\textsuperscript{139}. MitoDAMPs are detectable in cancers\textsuperscript{140,141}, thus implying that MitoDAMPs may impair NK cell function by depleting arginine in the TME.

**Tryptophan**

Tryptophan is an essential amino acid. Because mammalian cells are incapable of synthesizing tryptophan, dietary intake is the major source. Tryptophan is crucial for protein synthesis, and maintaining cell growth and proliferation, and is involved in the biosynthesis of the neurotransmitter serotonin and the hormone melatonin. More than 95% of free trypto-
phin serves as a substrate for the kynurenine pathway, in which tryptophan is degraded to nicotinic acid, the precur-
sor of nicotinamide adenine dinucleotide, a key coenzyme in energy metabolism and redox reactions\textsuperscript{142}. The first and rate limiting step of the kynurenine pathway is the degradation of tryptophan to N-formylkynurenine, catalyzed by the enzymes indoleamine 2,3-dioxygenase 1 and 2 (IDO1 and IDO 2), or the tryptophan-2,3-dioxygenase. N-formylkynurenine is then converted by N-formylkynurenine formidase to kynurenine, which is further catabolized to 3-hydroxykynurenine, quino-
linic acid, and picolinic acid\textsuperscript{142}. IDO1 is expressed in tumor associated myeloid cells\textsuperscript{143-145} and many tumor cells, including melanomas, and cervix, kidney, non-small lung and colorect-
al carcinomas\textsuperscript{142,146-148}. High expression of the tryptophan degrading enzyme IDO1 decreases the abundance of trypto-
phin in patients with breast cancer, colorectal cancer, head and neck cancer, prostate cancer, and lung cancer\textsuperscript{143}. Reciprocally, kynurenine levels are elevated in the plasma of patients with cancer\textsuperscript{143,149}.

**T cells**

T cells show less proliferation when cultured in trypto-
phan-free medium, IDO-conditioned medium, or medium supplemented with kynurenine and picolinic acid than in regular tryptophan-replete medium\textsuperscript{117,144,147,150}. Of note, the effects of tryptophan deprivation on T cell proliferation vary across experimental conditions. For example, the anti-CD3 or concanavalin A-driven proliferation of murine CD8\(^+\) T cells is inhibited when cells are cultured with kynurenine and low concentrations of tryptophan, and this effect is accom-
panied by diminished secretion of the cytokines IL-2 and IFN\(\gamma\)\textsuperscript{150}. In contrast, murine CD8\(^+\) T cells proliferate and produce cytokines normally when stimulated with PMA and ionomycin\textsuperscript{144,147,151}, thus suggesting that tryptophan deprivation affects T cell proliferation and cytokine production by impairing T cell receptor proximal signaling components. Furthermore, the observation that tryptophan deprivation induces an integrated stress response also depends on the experimental setting. Briefly, in the absence of amino acids, the general control nonderepressible 2 (GCN2) kinase is acti-
vated by the accumulation of uncharged tRNAs and triggers the integrated stress response\textsuperscript{152}. Exposure of murine CD8\(^+\) T cells to IDO-expressing DCs activates GCN2 kinase and results in complete inhibition of CD8\(^+\) T cell proliferation\textsuperscript{153}. Similarly, GCN2 kinase is activated in CD4\(^+\) T cells by trypto-
phan deprivation\textsuperscript{117}. In contrast to the two studies described above, GCN2 kinase activation is not observed in tumor-infiltrating T cells\textsuperscript{154}.

Beyond regulating T cell proliferation and stress responses, IDO regulates T cell differentiation. Co-culturing human CD4\(^+\) T cells with IDO-expressing DCs or cancer cells increases the differentiation of CD4\(^+\) CD25\(^+\) FoxP3\(^+\) T\(_{\text{reg}}\) cells with potent suppressor function\textsuperscript{147,155,156}. The enhanced T\(_{\text{reg}}\) cell differentiation is accompanied by increased production of IL-10 and TGF\(\beta\), and a reciprocal decrease in IL-4 and IFN\(\gamma\)\textsuperscript{150}. Inhibition of IDO suppresses T\(_{\text{reg}}\) cell differentiation, which is restored by the addition of kynurenine\textsuperscript{155,156}. IDO-
driven T\(_{\text{reg}}\) cell differentiation is dependent on the activation of the ligand-activated transcription factor AHR via kynuren-
ine binding\textsuperscript{157,158}. Kynurenine-mediated AHR activation upregulates PD-1 expression in tumor-infiltrating murine CD8\(^+\) T cells, thus conferring a CD8\(^+\) T cell exhaustion phe-
notype\textsuperscript{159,160}. Furthermore, tryptophan-derived metabolites, such as kynurenic acid and xanthurenic acid, also activate AHR\textsuperscript{161,162} and may contribute to T\(_{\text{reg}}\) cell differentiation and CD8\(^+\) T cell exhaustion.

The mechanisms through which IDO inhibits T cell pro-
liferation in vivo remain open to debate. One possibility is that IDO suppresses T cell responses simply by decreasing the availability of an important essential amino acid. The other possibility is that kynurenine, the product of an IDO-mediated enzymatic reaction, causes T cell inhibition. Mass spectroscopy analysis has demonstrated that intra-tumoral tryptophan con-
centrations are above the threshold triggering the integrated stress response\textsuperscript{154}. Thus, the in vivo immunosuppressive
function of tryptophan metabolism is likely not to be caused by tryptophan depletion\textsuperscript{154}.

**NK cells**

Tryptophan metabolism also affects NK cell proliferation and effector function. Culturing NK cells in the presence of purified IDO enzyme or co-culturing NK cells with IDO-expressing DCs inhibits NK cell proliferation. This inhibitory effect is partly restored by an IDO inhibitor\textsuperscript{143,147,163}. Similarly to that of T cells, NK cell cytotoxicity is inhibited by kynurenine. Kynurenine also decreases the expression of the NK cell activating receptor NKG2D and natural cytotoxicity triggering receptor 1 (NCR1, also known as NKp46)\textsuperscript{164}. In contrast, activating receptor NKG2D and natural cytotoxicity triggering receptor 9. Kynurenine also decreases the expression of the NK cell activating receptor NKG2D and natural cytotoxicity triggering receptor 1 (NCR1, also known as NKp46)\textsuperscript{164}. In contrast, activating receptor NKG2D and natural cytotoxicity triggering receptor 9.

**Grant support**

Guoliang Cui is supported by a CRI Lloyd J. Old STAR Award (Grant No. 3914), a Helmholtz Young Investigator Award (Grant No. VH-NG-1113), an EMBO Young Investigator Award, an Exploration Grant of the Boehringer Ingelheim Foundation (BIS), the German Research Foundation (DFG, Grant Nos. CU375/5-1, CU375/5-2, CU375/7-1, CU375/9-1, and 259332240/RTG2099), the German Cancer Aid Foundation (DKH, Grant Nos. 70113343 and 70114224), the Helmholtz Zukunftsthema Ageing and Metabolic Programming (AMPro, Grant No. ZT0026), HI-TRON Kick-Start Seed Funding (Grant No. HITR-2021-08), the Hector Foundation (Grant No. M20102), and an ERC Consolidator Award (Grant No. 101045416).

**Conflict of interest statement**

GC receives funding from Bayer and Boehringer Ingelheim.

**References**

1. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989; 245: 301-5.
2. Igney FH, Behrens CK, Krammer PH. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo. Int J Cancer. 2005; 113: 78-87.
3. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359: 1350-5.
4. Liu M, Sun Q, Wei F, Ren X. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biol Med. 2020; 17: 626-39.
5. Baumann D, Hagele T, Mochayedi J, Drebant J, Vent G, Blobner S, et al. Proinmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy. Nat Commun. 2020; 11: 2176.
6. Suarez-Carmona M, Williams A, Schreiber J, Hohmann N, Pruefer U, Krauss J, et al. Combined inhibition of CXCR1,2 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. J Immunother Cancer. 2021; 9.
7. Hanna BS, Llaó-Cid L, Iskar M, Roessner PM, Klett LC, Wong JKL, et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1(int)/TGF-1"+" CD8+ T cell population that sustains anti-tumor immunity. Immunology. 2021; 54: 2825-41.e10.
8. Weisshaar N, Wu J, Ming Y, Madi A, Hotz-Wagenblatt A, Ma S, et al. Rgs16 promotes antitumor CD8+ T cell exhaustion. Sci Immunol. 2022; 7: eabj1873.
9. Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szludowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; 592: 450-6.
10. Dudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, et al. Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH. Nature. 2021; 592: 444-9.
11. Yuan D, Huang S, Berger E, Liu L, Gross N, Heinzmann F, et al. Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell. 2017; 31: 771-89.e6.
12. Sektiglu IM, Carretero R, Bender N, Bogdan C, Garbi N, Umansky V, et al. Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. Oncoimmunology. 2016; 5: e1204506.
13. Madi A, Cui G. Regulation of immune cell metabolism by cancer cell oncogenic mutations. Int J Cancer. 2020; 147: 307-16.
14. Xu S, Chaudhary O, Rodriguez-Morales P, Sun X, Chen D, Zappasodi R, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. 2021; 54: 1561-77.e7.
15. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011; 478: 197-203.
16. Sadik A, Somarribas Patterson LF, Oztürk S, Mohapatra SR, Panitz V, Secker PF, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell. 2020; 182: 1252-70.e34.
17. Bunse L, Pasch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018; 24: 1192-203.
19. Rangel Rivera GO, Knochelmann HM, Dwyer CJ, Smith AS, Wyatt MM, Rivera-Reyes AM, et al. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Front Immunol. 2021; 12: 645242.

20. Lim AR, Rathmell WK, Rathmell JC. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife. 2020; 9: e55185.

21. Terren I, Orrantia A, Vitalle J, Zenarruzabaita O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019; 10: 2278.

22. Wu F, Cheng Y, Wu L, Zhang W, Zheng W, Wang Q, et al. Emerging landscapes of tumor immunity and metabolism. Front Oncol. 2020; 10: 575037.

23. Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159: 245-93.

24. Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaibed A, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 2017; 32: 377-91.e9.

25. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, Finkelstein D, et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35: 871-82.

26. Chang C-H, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015; 162: 1229-41.

27. Ho P-C, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita H, et al. Activation of peroxisome proliferator-activated receptor α and δ synergizes with inflammatory signals to enhance adoptive cell therapy. Cancer Res. 2019; 79: 445-51.

28. Manzo T, Prentice BM, Anderson KG, Raman A, Schalck A, Codreanu GS, et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. 2020; 217: e20191920.

29. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015; 6: 6692.

30. Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, et al. STAT3 activation-induced fatty acid oxidation in CD8+ T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab. 2020; 31: 148-61 e5.

31. Blagh J, Coulombe F, Vincent Emma E, Dupuy F, Galicia-Vázquez G, Yurchenko E, et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 2015; 42: 41-54.

32. Cham CM, Driessens G, O’Keefe JP, Gajewski TF. Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells. Eur J Immunol. 2008; 38: 2438-50.

33. Cham CM, Gajewski TF. Glucose availability regulates IFN-γ production and p7056 kinase activation in CD8+ effector T cells. J Immunol. 2005; 174: 4670-7.

34. Beier UH, Angelin A, Akimova T, Wang L, Liu Y, Xiao H, et al. Essential role of mitochondrial energy metabolism in Foxp3+ T regulatory cell function and allograft survival. FASEB J. 2015; 29: 2315-26.

35. Gerriets VA, Kishtan RJ, Johnson MO, Cohen S, Siska PJ, Nichols AG, et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol. 2016; 17: 1459-66.

36. Ho W, Coblstein SP, Adams E, Ten Bokum A, Necula AS, Zhang W, et al. Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight. 2017; 2: e89160.

37. Wu J, Ma S, Sandhoff R, Ming Y, Hotz-Wagenblatt A, Timmerman V, et al. Loss of neurological disease HSAN-I-associated gene SPTLC2 impairs CD8+ T cell responses to infection by inhibiting T cell metabolic fitness. Immunity. 2019; 50: 1218-31.e5.

38. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol. 2005; 42: S01-10.

39. Xu W, Zhang M. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016; 531: 651-5.

40. Schnell LS, Beloukha S, St-pack R, Wu J, et al. Loss of neurological disease HSAN-I-associated gene SPTLC2 impairs CD8+ T cell responses to infection by inhibiting T cell metabolic fitness. Immunity. 2019; 50: 1218-31.e5.

41. Yu X, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016; 531: 651-5.

42. Schnell LS, Beloukha S, St-pack R, Wu J, et al. Loss of neurological disease HSAN-I-associated gene SPTLC2 impairs CD8+ T cell responses to infection by inhibiting T cell metabolic fitness. Immunity. 2019; 50: 1218-31.e5.

43. Yu X, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X, et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016; 531: 651-5.
50. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology. 2013; 2: e22647.

51. Kobayashi T, Lam PY, Jiang H, Bednarska K, Gloury R, Murigneux V, et al. Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood. 2020; 136: 3004-17.

52. Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018; 19: 1330-40.

53. Assmann N, O’Brien KL, Donnelly RP, Dyck L, Zaitz-Bittencourt V, Loftus RM, et al. Srebp-controlled glucose metabolism is essential for nk cell functional responses. Nat Immunol. 2017; 18: 1197-206.

54. Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009; 27: 3330-7.

55. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d’Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma. Haematologica. 2011; 96: 269-76.

56. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008; 14: 1423-30.

57. Medrek C, Ponten F, Jirstrom K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012; 12: 306.

58. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol. 2011; 28: 1447-52.

59. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000; 164: 6166-73.

60. Webpage biorad; macrophage polarization mini-review. 2020.

61. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992; 176: 287-92.

62. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6: 13.

63. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med. 1983; 158: 670-89.

64. Colegio OR, Chu NQ, Szabo AL, Chu T, Rheebergen AM, Jairam V, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014; 513: 559-63.

65. Su P, Wang Q, Bi E, Ma X, Liu L, Yang M, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020; 80: 1438-50.

66. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res. 2011; 30: 62.

67. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol. 2000; 164: 762-7.

68. Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, et al. Impaired T cell function in malignant pleural effusion is caused by TGF-β derived predominantly from macrophages. Int J Cancer. 2016; 139: 2261-9.

69. Peng J, Tsang JY, Li D, Niu N, Ho DH, Lau KF, et al. Inhibition of TGF-β signaling in combination with TLR7 ligation reprograms a tumoricidal phenotype in tumor-associated macrophages. Cancer Lett. 2013; 331: 239-49.

70. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-9.

71. Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol. 2007; 1: 288-302.

72. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006; 66: 11238-46.

73. Yeo EJ, Cassetta L, Qian BZ, Lewkowich J, Li JF, Stefater JA 3rd, et al. Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Cancer Res. 2014; 74: 2962-73.

74. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010; 24: 241-55.

75. Vasiljeva O, Papazoglou A, Kruger A, Brodoefel H, Korovin M, Deussing J, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary carcinoma. Cancer Res. 2006; 66: 5242-50.

76. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol. 2004; 167: 769-81.

77. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007; 9: 893-904.

78. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr, Hajjar DP, et al. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Cell Biol. 2004; 167: 769-81.

79. Rios FJ, Koga MM, Peccinin M, Ferracini M, Giudlun M, Jancar S, Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediators Inflamm. 2013; 2013: 198193.

80. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998; 93: 229-40.
growth and invasiveness in prostate cancer. J Exp Med. 2022; 219: e20210564.

82. Divakaruni AS, Hsieh WY, Minarrieta L, Duong TN, Kim KKO, Desousa BR, et al. Etomoxir inhibits macrophage polarization by disrupting CoA homeostasis. Cell Metabolism. 2018; 28: 490-503.e7.

83. Wu H, Han Y, Rodriguez Sillike Y, Deng H, Siddiqui S, Treese C, et al. Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. EMBO Mol Med. 2019; 11: e1698.

84. Oishi Y, Spann NJ, Link VM, Muse ED, Strid T, Edillor C, et al. SREBP1 contributes to resolution of pro-inflammatory TLR4 signaling by reprogramming fatty acid metabolism. Cell Metab. 2017; 25: 412-27.

85. Ramirez CM, Torrecilla-Parra M, Pardo-Marques V, de-Frutos MF, Perez-Garcia A, Tabraue C, et al. Crosstalk between LXR and cavelon-1 signaling supports cholesterol efflux and anti-inflammatory pathways in macrophages. Front Endocrinol (Lausanne) 2021; 12: 635923.

86. Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gourirand V, et al. Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab. 2019; 29: 1376-89 e4.

87. James BR, Tomanek-Chalkley A, Askeland EJ, Kucaba T, Griffith TS, Morris CR, Hamilton-Reeves J, Martindale RG, Sarav M, Ochoa Hope HC, Salmond RJ. The role of non-essential amino acids in T cell function and anti-tumour immunity. Arch Immunol Ther Exp (Warsz). 2021; 69: 29.

88. Han C, Ge M, Ho PC, Zhang L. Fueling T-cell antitumor immunity: amino acid metabolism revisited. Cancer Immunol Res. 2021; 9: 1373-82.

89. Sullivan MR, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife. 2019; 8: e44235.

90. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020; 11: 938.

91. Morris SM, Jr. Arginine metabolism revisited. J Nutr. 2016; 146: 25795-865.

92. Chantranupong L, Scaria SM, Saxton RA, Gygi MP, Shen K, Wyant GA, et al. The CASTOR proteins are arginine sensors for the mTORC1 pathway. Cell. 2016; 165: 153-64.

93. Morris CR, Hamilton-Reeves J, Martindale RG, Sarav M, Ochoa Gautier JR. Acquired amino acid deficiencies: a focus on arginine and glutamine. Nutr Clin Pract. 2017; 32: 30s-47s.

94. Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A. Argininosuccinate synthetase from the urea cycle to the citrulline-N0 cycle. Eur J Biochem. 2003; 270: 1887-99.

95. Böger RH. The pharmacodynamics of L-arginine. J Nutr. 2007; 137: 16505-5S.

96. Lüneburg N, Xanthakis V, Schwedhelm E, Sullivan LM, Maas R, Anderssohn M, et al. Reference intervals for plasma L-arginine and the L-arginine: asymmetric dimethylarginine ratio in the Framingham offspring cohort. J Nutr. 2011; 141: 2186-90.

97. Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR, et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immunosuppression in the tumor microenvironment. J Immunother Cancer. 2017; 5: 101.

98. Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, et al. Targeting the arginine metabolic brake enhances immunotherapy for leukemia. Int J Cancer. 2019; 145: 2201-8.

99. Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood. 2015; 125: 2386-96.
113. Pan M, Reid MA, Lowman XH, Kulkarni RP, Tran TQ, Liu X, et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat Cell Biol. 2016; 18: 1090-101.

114. Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013; 122: 749-58.

115. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol. 2003; 170: 5064-74.

116. Gray MJ, Poljakovic M, Kepka-Lenhart D, Morris SM. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and G/C/E/BP. Gene. 2005; 353: 98-106.

117. Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui KO, et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A. 2009; 106: 12055-60.

118. Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, et al. Macrophage expression of hypoxia-inducible factor-1α suppresses T-cell function and promotes tumor progression. Cancer Res. 2010; 70: 7465-75.

119. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol. 2003; 171: 1232-9.

120. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazzuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004; 64: 5839-49.

121. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I–producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009; 69: 1553-60.

122. Crump NT, Hadjinicolaou AV, Xia M, Walsby-Tickle J, Gileadi U, Chen J-L, et al. Chromatin accessibility governs the differential response of cancer and T cells to arginase starvation. Cell Rep. 2021; 35: 109101.

123. Zea AH, Rodriguez PC, Culotta KS, Hernandez CP, DeSalvo J, Ochoa JB, et al. L-arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cell Immunol. 2004; 232: 21-31.

124. Munder M. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006; 108: 1627-34.

125. Fletcher M, Ramirez ME, Sierra RA, Raber P, Thevenot P, Al-Khami AA, et al. L-arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res. 2015; 75: 275-83.

126. Werner A, Koschke M, Leuchtner N, Luckner-Minden C, Habermeier A, Rupp J, et al. Reconstitution of T cell proliferation under arginine limitation: activated human T cells take up citrulline via L-type amino acid transporter 1 and use it to regenerate arginine after induction of arginosuccinate synthase expression. Front Immunol. 2017; 8: 864.

127. Werner A, Amann E, Schnitzius V, Habermeier A, Luckner-Minden C, Leuchtner N, et al. Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation. Eur J Immunol. 2016; 46: 92-103.

128. Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016; 167: 829-42.e13.

129. Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007; 109: 1568-73.

130. Baniyash M. TCR-ζ-chain downregulation: curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004; 4: 675-87.

131. Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol. 2003; 3: 973-83.

132. Eibert SM, Lee K-H, Pipkorn R, Sester U, Wabnitz GH, Giese T, et al. Cofilin peptide homologs interfere with immunological synapse formation and T cell activation. Proc Natl Acad Sci. 2004; 101: 1957-62.

133. Feldmeyer N, Wabnitz G, Leicht S, Luckner–Minden C, Schiller M, Franz T, et al. Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes. Int Immunol. 2012; 24: 303-13.

134. Zhang J, Xu X, Shi M, Chen Y, Yu D, Zhao C, et al. CD13( hi) neutrophil-like myeloid-derived suppressor cells exert immune suppression through arginase 1 expression in pancreatic ductal adenocarcinoma. Oncoimmunology. 2017; 6: e1258504.

135. Mao F-Y, Zhao Y-I, Lv Y-P, Teng Y-S, Kong H, Liu Y-G, et al. CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. Cell Death Dis. 2018; 9: 763.

136. Vonwirth V, Bulbul Y, Werner A, Echchannaoui H, Windschmitt J, Habermeier A, et al. Inhibition of arginase I liberates potent T cell immunostimulatory activity of human neutrophil granulocytes. Front Immunol. 2020; 11: 617699.

137. Lamas B, Vergnaud-Gauduchon J, Goncalves-Mendes N, Perche O, Rossary A, Vasson MP, et al. Altered functions of natural killer cells in response to L-arginine availability. Cell Immunol. 2012; 280: 182-90.

138. Oberlies J, Watzl C, Giese T, Luckner C, Kropf P, Muller I, et al. Regulation of NK cell function by human granulocyte arginase. J Immunol. 2009; 182: 5259-67.

139. Westhaver LP, Neresian S, Nelson A, MacLean LK, Carter EB, Rowter D, et al. Mitochondrial damage-associated molecular patterns trigger arginase-dependent lymphocyte immunoregulation. Cell Rep. 2022; 39: 110847.

140. Jain A, Bakhshi S, Thakkar H, Gerards M, Singh A. Elevated mitochondrial DNA copy numbers in pediatric acute lymphoblastic leukemia: a potential biomarker for predicting inferior survival. Pediatr Blood Cancer. 2018; 65: e26874.

141. Meng X, Schwarzenbach H, Yang Y, Muller V, Li N, Tian D, et al. Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer. Transl Oncol. 2019; 12: 1213-20.

142. Comai S, Bertazzo A, Brughera M, Crotti S. Tryptophan in health and disease. Adv Clin Chem. 2020; 95: 165-218.
143. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010; 115: 3520-30.

144. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999; 189: 1363-72.

145. Plattner M, Nollen EAA, Rohrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019; 18: 379-401.

146. Theate I, van Baren N, Pilotte L, Moulin P, Larrieu P, Renauld JC, et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res. 2015; 3: 161-72.

147. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002; 196: 459-68.

148. Peyraud F, Guegan J-P, Bodet D, Cousin S, Bessede A, Italiano A. Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives. Front Immunol. 2022; 13: 807271.

149. Puccetti P, Fallarino F, Italiano A, Soubeyran I, MacGrogan G, Debled M, et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS One. 2015; 10: e0122046.

150. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006; 176: 6752-61.

151. Fallarino F, Grohmann U, Hwang KW, Oraona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003; 4: 1206-12.

152. Costa-Mattioli M, Walter P. The integrated stress response: from mechanism to disease. Science. 2020; 368: eaat5314.

153. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. Gcn2 kinase in t cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22: 633-42.

154. Sonner JK, Deumelandt K, Ott M, Thome CM, Rauschenbach KJ, Schulz S, et al. The stress kinase Gcn2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology. 2016; 5: e1240858.

155. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol. 2008; 181: 5396-404.

156. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007; 109: 2871-7.

157. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010; 185: 3190-8.

158. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014; 32: 403-32.

159. Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation. Cancer Cell. 2018; 33: 480-94.e7.

160. Amobi-McCloud A, Muthuswamy R, Battaglia S, Yu H, Liu T, Wang J, et al. IDO1 expression in ovarian cancer induces PD-1 in T cells via aryl hydrocarbon receptor activation. Front Immunol. 2021; 12: 678999.

161. Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, Landesman E, et al. An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER-/ PR-/Her2- human breast cancer cells. Mol Pharmacol. 2016; 90: 674-88.

162. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzenza EM, et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 2010; 115: 89-97.

163. Cafferio M, Sorino C, Caruana I, Weber G, Camera A, Cifaldi L, et al. GD2 redirected CAR T and activated NK-cell-mediated secretion of ifngamma overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape. J Immunother Cancer. 2021; 9: e001502.

164. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKP46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006; 108: 4118-25.

165. Wang D, Saga Y, Mizukami H, Sato N, Nonaka H, Fujjwara H, et al. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012; 40: 929-34.

Cite this article as: Wißfeld J, Werner A, Yan X, ten Bosch N and Cui G. Metabolic regulation of immune responses to cancer. Cancer Biol Med. 2022; 19: 1528-1542. doi: 10.20892/j.issn.2095-3941.2022.0381